These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Zamorano L, Juan C, Fernández-Olmos A, Ge Y, Cantón R, Oliver A. Clin Microbiol Infect; 2010 Sep; 16(9):1482-7. PubMed ID: 20002107 [Abstract] [Full Text] [Related]
5. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158 [Abstract] [Full Text] [Related]
15. Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms. Jensen PØ, Briales A, Brochmann RP, Wang H, Kragh KN, Kolpen M, Hempel C, Bjarnsholt T, Høiby N, Ciofu O. Pathog Dis; 2014 Apr; 70(3):440-3. PubMed ID: 24376174 [Abstract] [Full Text] [Related]
16. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Henrichfreise B, Wiegand I, Luhmer-Becker I, Wiedemann B. Antimicrob Agents Chemother; 2007 Oct; 51(10):3642-9. PubMed ID: 17682103 [Abstract] [Full Text] [Related]